EuropaBio lobbies for better Orphan Drug r...EuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations. more ➔
AcquisitionVectivBio expands rare disease pipelineSwiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases. more ➔
Call for pull incentives to get startedWith new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality. more ➔
ADC Therapeutics: US$325m for ADC royaltie...ADC Therapeutics is set to receive up to US$325m for a royalty share in its antibody drug conjugates Zynlonta and Cami. more ➔
Cardior bags €64m in Series B FinancingCardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure. more ➔
Yet another blow to Mercks cancer hopefu...GSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results. more ➔
Beckley Psytech: €68m for psychedelic me...UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the companys pipeline of psychedelic compounds dedicated to addressing … more ➔
ERS Genomics and Cellular Engineering Tech...ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement. more ➔
Boehringer walks away from CureVac dealSetback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company. more ➔
New vaccine trial targets Covid variantsVaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001. more ➔
